Viking Therapeutics Inc Stock

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech company, went public almost 11 years ago. Since then, the drugmaker's stock has performed well, while it has made significant clinical

For stock investors, any beaten-down sector is worth combing through for bargains. These days, healthcare certainly qualifies; the S&P Composite 1500 Health Care index has ticked only marginally

The anti-obesity drug market is getting crowded. Many healthcare companies are working on their own GLP-1 drugs in an effort to take market share, which could amount to billions of dollars in

Every now and then, two investments land in front of you that look nothing alike but pose the same underlying questions: How much uncertainty are you willing to tolerate, and in what form? In that

Generally, when investors are looking for growth, they turn to industries such as technology. Here, revenue may be rising in the double or even triple digits, leading to explosive stock performance

On February 17, 2026, ACT Capital Management disclosed a new position in Viking Therapeutics (NASDAQ:VKTX), acquiring 206,100 shares worth $7.25 million.

According to an SEC filing dated February

Shares in Vikinig Therapeutics (NASDAQ: VKTX) rose by 16.5% in February, according to data from S&P Global Market Intelligence. The move helped the stock recover in 2026, and at the time of writing,

Some artificial intelligence (AI)-focused companies have delivered exceptional returns over the past few years, but some investors and analysts now believe we are in an AI bubble ready to burst.

In the 1990s, a group of research analysts worked at a prominent hedge fund, Tiger Management, led by the legendary investor Julian Robertson. After Tiger closed down, many of these analysts went on

Investors look to the recent moves of billionaires for one clear reason: They've demonstrated their knowledge of the stock market by choosing many winning investments over the years. But how do we

If you're looking to capitalize on the rapidly growing market for weight loss drugs, you can do so in different ways. One strategy is to invest in companies like Eli Lilly or Novo Nordisk that

If you're looking for the company-specific headline that sent shares of Viking Therapeutics (NASDAQ: VKTX) soaring today, don't bother. You won't find one. Rather, investors are proverbially

The weight loss drug market has been one key focus for investors in recent years. This is because demand has been incredibly high, driving blockbuster revenue for companies making such products --

Most veteran investors can attest that, although they're also often a complete bust, every now and then a biopharma stock dishes out a windfall gain.

That's what the analyst community seems to

Viking Therapeutics (NASDAQ: VKTX) is aiming to join one of the biggest growth industries of the times: the weight loss drug market. People hoping to lose weight have rushed to get in on GLP-1

When most people think about GLP-1 drugs, they think of the blockbuster products sold by pharma giants Eli Lilly and Novo Nordisk. Lilly makes Mounjaro and Zepbound, while Novo makes Ozempic and

Eli Lilly (NYSE: LLY) has crushed the market over the past decade, largely thanks to breakthroughs within its core therapeutic area. Some might think it's too late to invest in the stock. Eli Lilly

Royal Caribbean (NYSE: RCL) is set to launch a river cruise business through its upscale Celebrity brand, and demand has been so strong that the cruise line doubled its expected fleet size from 10

Obesity is a global health crisis and is a direct or indirect cause of various health conditions. The emergence of GLP-1 agonists over the past several years has ignited one of the most significant